Short description
ObsEva is a speciality biopharmaceutical company developing drugs for women’s reproductive medicine.
Description
ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor.
ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.
Last funding
Nopepepe
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Plan-les-ouates, Geneve, Switzerland, Europe
Founded on
January 1, 2012
Exited on
January 26, 2017
Went public on
January 26, 2017
Stock symbol
OBSV
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess, No Way, No Way, Nopepepe, Uh Ohhhh, No Way, Blurry Noaccess, Noaccess, Blurry Noaccess, Uh Ohhhh, Cannot Access, Noaccessforu, Cannot Access, Cannot Access, Nopepepe, Blurry Noaccess, Blurry Noaccess
Sign in for full access
Founders
André Chollet, Ernest Loumaye